Literature DB >> 4330006

The turnover and transport of vitamin D and of a polar metabolite with the properties of 25-hydroxycholecalciferol in human plasma.

J E Smith, D S Goodman.   

Abstract

Four normal men were injected intravenously with physiological doses (6 mug) of vitamin D(3)-1,2-(3)H. Serial samples of plasma were collected for 50 days. Total lipid extracts were chromatographed on silicic acid columns or thin-layer plates in order to characterize the radioactive components. Labeled vitamin D(3) disappeared rapidly from plasma (initial half-life approximately 12 hr); after 7 days unchanged vitamin D(3) represented less than 1% of circulating radioactivity. Coincident with vitamin D(3) disappearance a more polar labeled metabolite appeared with chromatographic and other properties identical with those of 25-hydroxycholecalciferol. The disappearance of the more polar metabolite was relatively slow with a half-life of 19.6 +/-0.6 days. A similar half-life was seen in a fifth subject, injected with 80 mug of vitamin D(3)-(3)H. Most (approximately 92%) of the plasma total radioactivity was represented by this component throughout the study. Plasma samples collected at various times were adjusted to density (d) 1.21 and were ultracentrifuged to separate plasma lipoproteins from proteins with d > 1.21. In all samples, almost all (mean 94%) of the radioactivity was found in association with proteins of d > 1.21. This observation was confirmed by bioassay, measuring uptake of (45)Ca by intestinal slices. All plasma bioassayable vitamin D was found in association with proteins of d > 1.21; 55% of bioactivity was found in the chromatographic fraction corresponding to 25-hydroxycholecalciferol and 44% in the fractions representing vitamin D(3). Since both vitamin D(3) and its 25-hydroxy metabolite are lipid-soluble sterol derivatives, the finding that these compounds do not circulate in association with the known plasma lipoproteins provides presumptive evidence for the existence of a specific transport protein of d > 1.21. The transport protein for the polar metabolite has been partly characterized by gel filtration on Sephadex G-200 and by electrophoresis on polyacrylamide gel. The protein has an apparent size slightly smaller than plasma albumin (approximate mol wt 50,000-60,000) and an electrophoretic mobility very slightly greater than that of albumin. Studies are in progress to fractionate further and to characterize the transport protein.

Entities:  

Mesh:

Substances:

Year:  1971        PMID: 4330006      PMCID: PMC292150          DOI: 10.1172/JCI106710

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  30 in total

1.  25-hydroxycholecalciferol. A biologically active metabolite of vitamin D3.

Authors:  J W Blunt; H F DeLuca; H K Schnoes
Journal:  Biochemistry       Date:  1968-10       Impact factor: 3.162

2.  Serum protein binding of vitamin D3.

Authors:  P S Chen; K Lane
Journal:  Arch Biochem Biophys       Date:  1965-10       Impact factor: 4.013

Review 3.  Fat transport in lipoproteins--an integrated approach to mechanisms and disorders.

Authors:  D S Fredrickson; R I Levy; R S Lees
Journal:  N Engl J Med       Date:  1967-01-05       Impact factor: 91.245

4.  Vitamin D activity in normal human serum and serum proteins.

Authors:  P de Crousaz; B Blanc; I Antener
Journal:  Helv Odontol Acta       Date:  1965-10

5.  Transport of lysolecithin by albumin in human and rat plasma.

Authors:  S Switzer; H A Eder
Journal:  J Lipid Res       Date:  1965-10       Impact factor: 5.922

6.  An in vivo study of the carrier proteins of 3H-vitamins D3 and D4 in rat serum.

Authors:  H Rikkers; H F DeLuca
Journal:  Am J Physiol       Date:  1967-08

7.  Fatty acid composition of human plasma lipoprotein fractions.

Authors:  D S Goodman; T Shiratori
Journal:  J Lipid Res       Date:  1964-07       Impact factor: 5.922

8.  Retinol-binding protein: the transport protein for vitamin A in human plasma.

Authors:  M Kanai; A Raz; D S Goodman
Journal:  J Clin Invest       Date:  1968-09       Impact factor: 14.808

9.  Metabolism of vitamin D3-3H in vitamin D-resistant rickets and familial hypophosphatemia.

Authors:  L V Avioli; T F Williams; J Lund; H F DeLuca
Journal:  J Clin Invest       Date:  1967-12       Impact factor: 14.808

10.  Metabolism of vitamin D3-3H in human subjects: distribution in blood, bile, feces, and urine.

Authors:  L V Avioli; S W Lee; J E McDonald; J Lund; H F DeLuca
Journal:  J Clin Invest       Date:  1967-06       Impact factor: 14.808

View more
  37 in total

Review 1.  Chemistry of the retinoid (visual) cycle.

Authors:  Philip D Kiser; Marcin Golczak; Krzysztof Palczewski
Journal:  Chem Rev       Date:  2013-07-11       Impact factor: 60.622

Review 2.  Clinical review: The role of the parent compound vitamin D with respect to metabolism and function: Why clinical dose intervals can affect clinical outcomes.

Authors:  Bruce W Hollis; Carol L Wagner
Journal:  J Clin Endocrinol Metab       Date:  2013-10-08       Impact factor: 5.958

Review 3.  The clinical use of vitamin D metabolites and their potential developments: a position statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the International Osteoporosis Foundation (IOF).

Authors:  Luisella Cianferotti; Claudio Cricelli; John A Kanis; Ranuccio Nuti; Jean-Y Reginster; Johann D Ringe; Rene Rizzoli; Maria Luisa Brandi
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

Review 4.  Vitamin D administration during pregnancy as prevention for pregnancy, neonatal and postnatal complications.

Authors:  Carol L Wagner; Bruce W Hollis; Kalliopi Kotsa; Hana Fakhoury; Spyridon N Karras
Journal:  Rev Endocr Metab Disord       Date:  2017-09       Impact factor: 6.514

5.  Serum concentrations of 25-hydroxy vitamin D in Europeans and Asians after oral vitamin D3.

Authors:  G Ellis; W T Cooke
Journal:  Br Med J       Date:  1978-03-18

6.  Vitamin D supplementation protects against bone loss following inhalant organic dust and lipopolysaccharide exposures in mice.

Authors:  Anand Dusad; Geoffrey M Thiele; Lynell W Klassen; Dong Wang; Michael J Duryee; Ted R Mikuls; Elizabeth B Staab; Todd A Wyatt; William W West; Stephen J Reynolds; Debra J Romberger; Jill A Poole
Journal:  Immunol Res       Date:  2015-05       Impact factor: 2.829

7.  Significance of serum level of 25-hydroxycholecalciferol in gastrointestinal disease.

Authors:  M S Schoen; J Lindenbaum; M S Roginsky; P R Holt
Journal:  Am J Dig Dis       Date:  1978-02

8.  Vitamin D treatment modulates organic dust-induced cellular and airway inflammatory consequences.

Authors:  Gregory A Golden; Todd A Wyatt; Debra J Romberger; Daniel Reiff; Michael McCaskill; Christopher Bauer; Angela M Gleason; Jill A Poole
Journal:  J Biochem Mol Toxicol       Date:  2012-12-20       Impact factor: 3.642

Review 9.  Does vitamin D make the world go 'round'?

Authors:  Carol L Wagner; Sarah N Taylor; Bruce W Hollis
Journal:  Breastfeed Med       Date:  2008-12       Impact factor: 1.817

10.  Changes in 25-Hydroxyvitamin D3 to oral treatment with vitamin D3 in postmenopausal females with osteoporosis.

Authors:  H C Hoeck; B Li; P Qvist
Journal:  Osteoporos Int       Date:  2008-12-13       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.